APG Asset Management
NBIX icon

APG Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

APG Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
69,920
+18,761
+37% +$2.78M 0.03% 383
2026
Q1 		$5.85M Sell
51,159
-8,129
-14% -$1.08M 0.02% 419
2025
Q4 		$7.16M Sell
59,288
-1,720
-3% -$249K 0.02% 395
2025
Q3 		$7.29M Buy
61,008
+430
+0.7% +$58.3K 0.02% 394
2025
Q2 		$6.49M Buy
60,578
+2,636
+5% +$302K 0.02% 416
2025
Q1 		$5.93M Sell
57,942
-2,247
-4% -$285K 0.02% 428
2024
Q4 		$7.93M Buy
+60,189
New +$7.44M 0.02% 402
2024
Q3 		– Sell
-257,315
Closed -$33.1M – 568
2024
Q2 		$33.1M Sell
257,315
-119,803
-32% -$16.4M 0.06% 270
2024
Q1 		$48.2M Sell
377,118
-5,426
-1% -$741K 0.08% 217
2023
Q4 		$45.6M Buy
382,544
+46,685
+14% +$5.37M 0.09% 217
2023
Q3 		$37.8M Buy
335,859
+21,378
+7% +$2.25M 0.08% 241
2023
Q2 		$27.2M Sell
314,481
-12,265
-4% -$1.2M 0.05% 292
2023
Q1 		$30.4M Buy
326,746
+15,466
+5% +$1.61M 0.06% 285
2022
Q4 		$37.2M Buy
311,280
+76,960
+33% +$9.01M 0.07% 289
2022
Q3 		$25.4M Sell
234,320
-89,056
-28% -$9.04M 0.07% 278
2022
Q2 		$30.2M Buy
323,376
+1,466
+0.5% +$135K 0.07% 278
2022
Q1 		$27.1M Sell
321,910
-600
-0.2% -$50.9K 0.05% 317
2021
Q4 		$24.2M Buy
322,510
+314,900
+4,138% +$29M 0.04% 348
2021
Q3 		$630K Sell
7,610
-1,500
-16% -$142K ﹤0.01% 846
2021
Q2 		$748K Sell
9,110
-109,346
-92% -$10.5M ﹤0.01% 830
2021
Q1 		$9.8M Sell
118,456
-47,837
-29% -$5.02M 0.02% 487
2020
Q4 		$13M Sell
166,293
-20,695
-11% -$2M 0.02% 514
2020
Q3 		$15.3M Buy
186,988
+45,409
+32% +$5.25M 0.03% 493
2020
Q2 		$15.4M Buy
141,579
+40,000
+39% +$4.42M 0.03% 460
2020
Q1 		$8.79M Buy
101,579
+46,579
+85% +$4.56M 0.02% 577
2019
Q4 		$5.27M Buy
+55,000
New +$5.76M 0.01% 689

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APG Asset Management's NBIX Position: Q2 2026 in Review

APG Asset Management increased its Neurocrine Biosciences (NBIX) stake by 37% in Q2 2026, buying an estimated $2.78M and bringing the position to 69,920 shares worth $10.3M. The position accounts for 0.03% of the portfolio, ranked #383.

APG Asset Management first reported a position in NBIX in Q4 2019 and has held it in 26 quarters since. The position peaked at $48.2M in Q1 2024. 624 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • APG Asset Management held 69,920 shares of Neurocrine Biosciences worth $10.3M as of Q2 2026.
  • APG Asset Management bought 18,761 Neurocrine Biosciences shares in Q2 2026, an estimated $2.78M.
  • Neurocrine Biosciences made up 0.03% of APG Asset Management's portfolio in Q2 2026, its #383 holding.
  • APG Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 26 quarters since.
  • APG Asset Management's Neurocrine Biosciences position peaked at $48.2M in Q1 2024.
  • 624 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on APG Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.